Factor V Leiden Mutation and Implantation Failure

The purpose of this study is to determine whether inherited thrombophilias (tendency toward blood clotting) increase the risk of failure of the embryo to implant in IVF. The specific condition to be studied is the presence or absence of the Leiden mutation of the Factor V gene.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

University of Pennsylvania Reproductive Research Unit

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women undergoing in-vitro fertilization with successful ovarian hyperstimulation, oocyte retrieval, and fertilization
Transfer of at least 2 fresh embryos of Grade 2 (preembryo with blastomeres of equal size and <=10% cytoplasmic fragmentation) or better

Exclusion criteria

Infertility due to uterine anatomic defect
Current use of anticoagulant medication, such as heparin or aspirin
Known presence of any other condition associated with increased risk of thrombosis

Treatment and study plan

Test for Factor V Leiden gene mutation

Procedure

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

Evaluation of the Role of Factor V Leiden Mutation in Implantation Failure

Important dates

Study start: 2001
Study completion: 2005
First posted: Sep 19, 2005
Registry last updated: Aug 9, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed